急性心肌梗死和脑梗死患者血浆中ADAMTS13的测定及意义

Determination of ADAMTS13 antigen and activity levels in patients with acute myocardial infarction and acute ischemic stroke

目的研究急性心肌梗死（AMI）及急性脑梗死（AIS）患者血浆中血管性血友病因子（vWF）裂解酶（ADAMTS13）抗原和活性变化情况，探讨ADAMTS13在动脉血栓性疾病患者发病中的作用及意义。方法用Frests—WF73试剂盒检测血浆中ADAMTS13的活性；用ELISA法检测ADAMTS13抗原含量；并对患者血浆vWF多聚物进行电泳分析。结果正常对照组、AMI组和AIS组ADAMTS13抗原含量分别为（878±198）、（618±188）和（702±155）U／L；活性分别为（81．7±13．9）％，（59．2±22．1）％和（65．4±15．8）％。AMI组和AIS组ADAMTS13抗原含量及活性均显著低于正常对照组（P〈0．01）；vWF多聚物分析未见异常。结论AMI及AIS患者血浆ADMATS13抗原及活性均降低，提示ADAMTS13的减少与动脉血栓性疾病的发病相关。

Objective To investigate the ADAMTS13 antigen levels and activity in patients with acute myocardial infarction （AMI） and acute ischemic stroke （ AIS）, and explore its significance in these diseases. Methods ADAMTS13 activity levels were detected by a new developed Frests-vWF73 kit, ADAMTS13 antigen levels by ELISA kit, and vWF muhimers by electrophoresis. Results ADAMTS13 antigen in normal control, AMI and AIS was （878 ± 198）, （618 ± 188） and （702 ± 155） U/L, and ADAMTS13 activity was （ 81.7 ± 13.9） % , （ 59.2 ± 22.1 ） % and （65.4 ± 15.8 ） % , respectively, being significantly decreased in AMI and AIS patients. Conclusion ADMATS13 might involve in arterial infarction diseases.